Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Brain tumor surgery at recurrence: does it help?

NCT ID NCT02394626

Knowledge-focused Sponsor: Insel Gruppe AG, University Hospital Bern Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at whether surgery can help people whose glioblastoma has come back after initial treatment. 120 participants will be randomly assigned to either have surgery followed by second-line therapy, or to have second-line therapy alone. The goal is to see if surgery improves overall survival, neurological function, and quality of life.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
surgery (craniotomy and tumor resection)
What this could lead to
If successful, this trial could provide the first strong evidence that surgery for recurrent glioblastoma extends survival, potentially changing standard care.
What could go wrong
This is a phase 2 trial with only 120 participants, so results are preliminary. Past retrospective studies have been mixed, and surgery carries risks like infection or neurological damage.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 120 people

The number the study aims to enrol. It can still change while the study runs.

Started

May 2015

Expected to finish

Dec 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Written informed consent * ≥18 years of age * Prior resection of glioblastoma confirmed by histology * Glioblastoma pretreated with standard radiotherapy without or with temozolomide * First progression according to RANO criteria * First progression not within 3 months after completion of radiation therapy * Complete removal of contrast-enhancing lesion considered feasible without significant risk of permanent speech or motor function according to MRI as confirmed by study eligibility committee after screening and prior to recruitment * No encroachment of the M1 or A1 segments of the medial and anterior cerebral artery on MRI * No contrast enhancement in presumed speech and primary motor areas on MRI * No midline shift on MRI * No contrast enhancing ventricular spread, multifocal recurrence, meningeosis carcinomatosa or infiltration of the contra-lateral hemisphere on MRI * No contra-indication for surgery * Good functional status (KPS ≥ 70) Exclusion Criteria

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Glioblastoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

glioblastoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Glioblastoma

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    25 sites in 9 countries. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Assistance Publique - Hôpitaux de Marseille, Department of Neuro-Oncology

    RECRUITING

    Marseille, France

  • Assistance Publique - Hôpitaux de Paris (AP-HP), Department of Neurosurgery

    RECRUITING

    Paris, France

  • Centre Hospitalier Régional et Universitaire de Tours (CHRU Tours), Department of Neurosurgery

    RECRUITING

    Tours, France

  • Centre Hospitalier Universitaire Dijon Bourgogne, Department of Neurosurgery

    RECRUITING

    Dijon, France

  • Centre Hospitalier Universitaire de Nice, Department of Neurosurgery

    RECRUITING

    Nice, France

  • Centre Hospitalier Universitaire de Saint-Étienne, Department of Neurosurgery

    RECRUITING

    Saint-Etienne, France

  • Dep. of Neurosurgery, Bern University Hospital

    RECRUITING

    Bern, 3010, Switzerland

  • Dep. of Neurosurgery, Centre hospitalier universitaire vaudois

    RECRUITING

    Lausanne, 1011, Switzerland

  • Department of Neurosurgery, Amsterdam University Medical Center

    RECRUITING

    Amsterdam, Netherlands

  • Department of Neurosurgery, Centro Hospitalar Universitário Lisboa Norte - Hospital de Santa Maria

    RECRUITING

    Lisbon, 1649-035, Portugal

  • Department of Neurosurgery, Haaglanden Medical Center, The Hague

    RECRUITING

    The Hague, Netherlands

  • Department of Neurosurgery, Hospital of Larissa & General Hospital of Larissa

    RECRUITING

    Larissa, 412 21, Greece

  • Department of Neurosurgery, L'Hospitalet de Llobregat, Barcelona

    RECRUITING

    Barcelona, Spain

  • Department of Neurosurgery, Radboud University Medical Center, Nijmegen

    RECRUITING

    Nijmegen, Netherlands

  • Helios Klinikum Erfurt

    RECRUITING

    Erfurt, 99089, Germany

  • Hospices Civils de Lyon - CHU de Lyon, Department of Neuro-Oncology

    RECRUITING

    Lyon, France

  • Institut de Cancérologie Strasbourg Europe (ICANS), Department of Oncology

    RECRUITING

    Strasbourg, France

  • Johannes Kepler University Linz University, Clinic for Neurosurgery

    RECRUITING

    Linz, Austria

  • Medical University of Vienna, Department of Neurosurgery

    RECRUITING

    Vienna, Austria

  • Ospedale Regionale di Lugano

    RECRUITING

    Lugano, 6900, Switzerland

  • University Hospital of Umeå, Department of Diagnostics and Intervention

    NOT_YET_RECRUITING

    Umeå, Sweden

  • University of Gothenburg, Department of Clinical Neuroscience

    NOT_YET_RECRUITING

    Gothenburg, Sweden

  • Universitätsklinikum Innsbruck

    RECRUITING

    Innsbruck, Austria

  • Universitätsklinikum Münster

    RECRUITING

    Münster, 48149, Germany

  • Universitätsspital Basel

    RECRUITING

    Basel, 4031, Switzerland

More trials for these conditions

Other studies related to the condition(s) this trial covers.